Evaluating risks and benefits of both strategies (to transplant or not to transplant) in patients with stable disease, it could be suitable to distinguish GATA2 deficient patients who undergo HSCT for bone marrow failure or immunodeficiency from patients who undergo HSCT for high-risk MDS or acute leukemia. This evidence concerns the gene GATA2 and acute leukemia.